


Do Biotech Investors stick to their Home Market?

Zurich, August 2019: In the first half of 2019, more funding rounds were completed by US investors (551) than European investors (147). Biotech and Medtech were the main sectors and accounted for 85% of total life science company investments across Europe and the US. Interestingly, European-based funds invested almost equally in European and US companies, while US funds invested 13 times more frequent in US companies than European companies (93% vs 7%).



Source: Biotechgate.com

The graph above shows the proportion of investment rounds in the US and Europe by US- and European-based investors for the first 6 months of 2019. The dataset includes all company sectors in the database (life science industry, incl. Biotech, Healthtech, Pharma and Medtech). The proportions may alter as new information on investments is received.

The top 5 investors of 2019 are all US-based and invested exclusively in local companies with the exception of Perceptive Advisors and Johnson & Johnson Innovation. The first invested in one Belgian Biotech company (Confo Therapeutics), while the latter invested in a UK Biotech company (Inivata), a VC fund (Medicixi) and one Swiss Biotech (Calypso Biotech).

Top Investors 2019			
Investor	Number of Investments in		
	Europe	USA	Total
Alexandria Venture Investments		17	17
Boxer Capital LLC		9	9
Deerfield Management Company		8	8
Perceptive Advisors	1	7	8
Johnson & Johnson Innovation - JJDC, Inc. (JJDC)	3	5	8

Source: Biotechgate.com